^
Association details:
| Biomarker: | PD-L1 expression + HER-2 overexpression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Margenza (margetuximab-cmkb) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MacroGenics Announces Lancet Oncology Publication of Margetuximab Data in Gastric Cancer
Published date:
07/09/2020
Excerpt:
The most pronounced benefit was observed in patients whose tumors had high HER2 expression at diagnosis (HER2 IHC3-positive) and were PD-L1-positive. In this double-positive subgroup, the ORR was 44% (11/25 patients) and the DCR was 72% (18/25 patients). Median PFS was 4.8 months (95% CI 1.6–13.9) and median OS was 20.5 months (95% CI 8.1–NR).
Trial ID:
